58553-48-3

Basic information

• Product Name: 2-CYANO-5-HYDROXYMETHYLPYRIDINE
• Synonyms: 5-(hydroxyMethyl)picolinonitrile;5-(hydroxyMethyl)-2-Pyridinecarbonitrile;5-(HydroxyMethyl)pyridine-2-carbonitrile
• CAS NO: 58553-48-3
• Molecular Formula: C₇H₆N₂O
• Molecular Weight: 134.14
• Mol File: 58553-48-3.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 353.8°Cat760mmHg
• Flash Point: 167.8°C
• Appearance: /
• Density: 1.25g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-CYANO-5-HYDROXYMETHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CYANO-5-HYDROXYMETHYLPYRIDINE(58553-48-3)
• EPA Substance Registry System: 2-CYANO-5-HYDROXYMETHYLPYRIDINE(58553-48-3)

Safety Data

• Hazardous Substances Data: 58553-48-3(Hazardous Substances Data)

Usage

General Description

2-Cyano-5-hydroxymethylpyridine is a chemical compound categorized under the class of organic compounds known as pyridines and derivatives. Pyridines are compounds containing a pyridine ring, a six-membered aromatic heterocycle which consists of one nitrogen atom and five carbon atoms. In this specific compound, along with the pyridine ring, it has a cyanide group (carbon triple-bonded to nitrogen) attached at the 2nd position and a hydroxymethyl group (-CH2OH) which is a compound functional group that consists of a hydroxy group (-OH) and methyl group (-CH2-), attached at the 5th position of the pyridine ring. Due to its chemical structure, the properties and applications of the compound can vary widely, potentially used in chemical synthesis or as a building block in the pharmaceutical industry.

InChI:InChI=1/C7H6N2O/c8-3-7-2-1-6(5-10)4-9-7/h1-2,4,10H,5H2

Upstream product

• 131747-37-0 3-Acetoxymethyl-6-cyanopyridine 
• 114951-34-7 3-Acetoxymethylpyridine-N-oxide 
• 70165-31-0 6-cyanonicotinic acid 
• 1620-77-5 5-methylpicolinonitrile 
• 887579-62-6 5-cyano-3-pyridinecarboxylic acid 
• 89809-65-4 methyl 6-cyanopyridine-3-carboxylate 
• 149806-06-4 6-bromonicotinaldehyde 
• 131747-68-7 2-cyanopyridine-5-carboxyaldehyde 
• 26218-78-0 methyl 6-bromonicotinate 
• 557-21-1 zinc(II) cyanide 
• 122306-01-8 2-bromo-5-(hydroxymethyl)pyridine 

Downstream Products

• 131747-68-7 2-cyanopyridine-5-carboxyaldehyde 
• 108337-86-6 2,6-dimethyl-4-(6-cyano-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester 
• 105954-37-8 5-chloromethyl-pyridine-2-carbonitrile 
• 1225380-31-3 5-(chloromethyl)pyridine-2-carbonitrile hydrochloride 
• 421551-72-6 (6-cyanopyridin-3-yl)methyl methanesulfonate 
• 302341-61-3 tert-bulyl N-[(6-cyanopyridin-3-yl)methyl]carbamate 
• 609345-79-1 5-(aminomethyl)pyridine-2-carboximidamide 
• 181130-14-3 5-(aminomethyl)pyridine-2-carbonitrile 

Relevant articles and documents

Heterocyclic phosphodiesterase inhibitor and uses thereof

The present invention belongs to the technical field of medicine, and particularly relates to a heterocyclic phosphodiesterase inhibitor compound represented by a formula (I), or a pharmaceutically acceptable salt and a stereoisomer thereof, and a pharmaceutical preparation, a pharmaceutical composition and applications of the compound, wherein R1, R2, R3, R4, ring A, m and n are defined in the specification. According to the present invention, the compound can be used for preparing drugs for treatment or prevention of diseases associated with PDE9 kinase.

Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use

In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, m, n, p, -L1-, -L2-, and -L3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

HETEROCYCLIC DERIVATIVES

The invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.